{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:10:41Z","timestamp":1787062241997,"version":"build-2736575974"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"\n Importance<\/jats:title>\n Transcatheter aortic valve replacement (TAVR) is an established treatment option for many patients with severe symptomatic aortic stenosis; however, debris dislodged during the procedure can cause embolic stroke. The Sentinel cerebral embolic protection (CEP) device is approved for capture and removal of embolic material during TAVR but its efficacy has been debated.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To explore regional differences in the association of CEP utilization with stroke outcomes in patients undergoing TAVR.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This post hoc analysis of a prospective, postmarket, randomized clinical trial evaluating TAVR performed with or without the CEP took place at 51 hospitals in the US, Europe, and Australia from February 2020 to January 2022. Patients with symptomatic aortic stenosis treated with transfemoral TAVR were included. Randomization was stratified according to center, operative risk, and intended TAVR valve type. Patients were excluded if the left common carotid or brachiocephalic artery had greater than 70% stenosis or if the anatomy precluded placement of the CEP device. Data for this post hoc study were analyzed from August to October 2024.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n TAVR with or without CEP.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was the rate of all stroke events at hospital discharge or 72 hours post-TAVR, whichever came first. Neurological examinations were performed at baseline and postprocedure to identify stroke, disabling stroke, and other neurological outcomes.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The Stroke Protection With Sentinel During Transcatheter Aortic Valve Replacement (PROTECTED TAVR) trial enrolled and randomized 3000 patients (1803 [60.1%] male; mean [SD] age, 78.9 [7.8] years): 1833 in the US cohort (TAVR alone: 919, TAVR with CEP: 914) and 1167 patients in the outside the US (OUS) cohort (TAVR alone: 580, TAVR with CEP: 587). Patients in the US cohort were younger, more predominantly male, had a lower prevalence of atrial fibrillation, and had a higher prevalence of bicuspid aortic valve, diabetes, and peripheral vascular disease compared with the OUS cohort. In the main trial, the incidence of stroke within 72 hours after TAVR or before discharge did not differ significantly between the CEP group and the control group, and there was no interaction by geographic region. In this post hoc analysis, patients treated with CEP in the US cohort exhibited a 50% relative risk reduction for overall stroke and a 73% relative risk reduction for disabling stroke compared to TAVR alone; a treatment effect on stroke risk reduction was not observed in the OUS cohort.<\/jats:p>\n <\/jats:sec>\n \n Conclusion and Relevance<\/jats:title>\n The PROTECTED TAVR trial could not show that the use of CEP had a significant effect on the incidence of periprocedural stroke during TAVR. Although there was no significant interaction by geographic region, this exploratory post hoc analysis suggests a trend toward greater stroke reduction in the US cohort but not in the OUS cohort. These findings are hypothesis generating, and further research is needed to determine if regional differences in patient characteristics or procedural practices affect CEP efficacy.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04149535<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamacardio.2024.4278","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T15:30:22Z","timestamp":1730215822000},"page":"17","source":"Crossref","is-referenced-by-count":18,"title":["Cerebral Embolic Protection by Geographic Region"],"prefix":"10.1001","volume":"10","author":[{"given":"Raj R.","family":"Makkar","sequence":"first","affiliation":[{"name":"Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakriti","family":"Gupta","sequence":"additional","affiliation":[{"name":"Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Waggoner","sequence":"additional","affiliation":[{"name":"US Heart & Vascular, Tucson Medical Center Healthcare, Tucson, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Horr","sequence":"additional","affiliation":[{"name":"Centennial Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhana","family":"Karha","sequence":"additional","affiliation":[{"name":"Baylor Scott & White, College Station, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowell","family":"Satler","sequence":"additional","affiliation":[{"name":"Washington Hospital Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Stoler","sequence":"additional","affiliation":[{"name":"Baylor Heart & Vascular Hospital, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Methodist Healthcare System, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Sakhuja","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"MacDonald","sequence":"additional","affiliation":[{"name":"South Denver Heart Center, Littleton, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Modolo","sequence":"additional","affiliation":[{"name":"Boston Scientific Corporation, Marlborough, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin B.","family":"Leon","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Linke","sequence":"additional","affiliation":[{"name":"University of Technology Dresden, Heart Center, University Hospital, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir R.","family":"Kapadia","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"17","key":"hoi240072r1","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1008232","article-title":"Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery.","volume":"363","author":"Leon","year":"2010","journal-title":"N Engl J Med"},{"issue":"23","key":"hoi240072r2","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa1103510","article-title":"Transcatheter versus surgical aortic-valve replacement in high-risk patients.","volume":"364","author":"Smith","year":"2011","journal-title":"N Engl J Med"},{"issue":"19","key":"hoi240072r3","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.jacc.2014.02.556","article-title":"Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery.","volume":"63","author":"Popma","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"hoi240072r4","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMoa1400590","article-title":"Transcatheter aortic-valve replacement with a self-expanding prosthesis.","volume":"370","author":"Adams","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"hoi240072r5","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1514616","article-title":"Transcatheter or surgical aortic-valve replacement in intermediate-risk patients.","volume":"374","author":"Leon","year":"2016","journal-title":"N Engl J Med"},{"issue":"10034","key":"hoi240072r6","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/S0140-6736(16)30073-3","article-title":"Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis.","volume":"387","author":"Thourani","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"hoi240072r7","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1001\/jamacardio.2016.2257","article-title":"Outcomes in the Randomized CoreValve US Pivotal High Risk Trial in patients with a society of thoracic surgeons risk score of 7% or less.","volume":"1","author":"Reardon","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"21","key":"hoi240072r8","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2307447","article-title":"Transcatheter aortic-valve replacement in low-risk patients at five years.","volume":"389","author":"Mack","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"hoi240072r9","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1910555","article-title":"Five-year outcomes of transcatheter or surgical aortic-valve replacement.","volume":"382","author":"Makkar","year":"2020","journal-title":"N Engl J Med"},{"issue":"10252","key":"hoi240072r10","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S0140-6736(20)31358-1","article-title":"Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trial.","volume":"396","author":"Makkar","year":"2020","journal-title":"Lancet"},{"issue":"23","key":"hoi240072r11","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2019.7525","article-title":"Association between transcatheter aortic valve replacement and early postprocedural stroke.","volume":"321","author":"Huded","year":"2019","journal-title":"JAMA"},{"issue":"21","key":"hoi240072r12","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/j.jacc.2020.09.595","article-title":"STS-ACC TVT registry of transcatheter aortic valve replacement.","volume":"76","author":"Carroll","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi240072r13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1212\/CPJ.0000000000000856","article-title":"Appraisal of health states worse than death in patients with acute stroke.","volume":"11","author":"Everett","year":"2021","journal-title":"Neurol Clin Pract"},{"issue":"6","key":"hoi240072r14","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1161\/01.STR.32.6.1425","article-title":"The utility of health states after stroke: a systematic review of the literature.","volume":"32","author":"Post","year":"2001","journal-title":"Stroke"},{"issue":"21","key":"hoi240072r15","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.jacc.2022.08.787","article-title":"National trends in TAVR and SAVR for patients with severe isolated aortic stenosis.","volume":"80","author":"Sharma","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"hoi240072r16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.118.007546","article-title":"Predictors, incidence, and outcomes of patients undergoing transfemoral transcatheter aortic valve implantation complicated by stroke.","volume":"12","author":"Vlastra","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"issue":"4","key":"hoi240072r17","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1161\/CIRCULATIONAHA.113.004103","article-title":"Characterization of neurological injury in transcatheter aortic valve implantation: how clear is the picture?","volume":"129","author":"Fanning","year":"2014","journal-title":"Circulation"},{"issue":"22","key":"hoi240072r18","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1161\/CIRCULATIONAHA.112.001091","article-title":"Histopathology of embolic debris captured during transcatheter aortic valve replacement.","volume":"127","author":"Van Mieghem","year":"2013","journal-title":"Circulation"},{"issue":"6","key":"hoi240072r19","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/jama.2016.10302","article-title":"Effect of a cerebral protection device on brain lesions following transcatheter aortic valve implantation in patients with severe aortic stenosis: the CLEAN-TAVI randomized clinical trial.","volume":"316","author":"Haussig","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"hoi240072r20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.4244\/EIJV12I4A84","article-title":"Filter-based cerebral embolic protection with transcatheter aortic valve implantation: the randomised MISTRAL-C trial.","volume":"12","author":"Van Mieghem","year":"2016","journal-title":"EuroIntervention"},{"issue":"4","key":"hoi240072r21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jacc.2016.10.023","article-title":"Protection against cerebral embolism during transcatheter aortic valve replacement.","volume":"69","author":"Kapadia","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"hoi240072r22","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJMoa2204961","article-title":"Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement.","volume":"387","author":"Kapadia","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"hoi240072r23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.123.013697","article-title":"Impact of cerebral embolic protection devices on disabling stroke after TAVR: updated results from the STS\/ACC TVT Registry.","volume":"17","author":"Butala","year":"2024","journal-title":"Circ Cardiovasc Interv"},{"issue":"6","key":"hoi240072r24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jacc.2016.11.045","article-title":"Proposed standardized neurological endpoints for cardiovascular clinical trials: an Academic Research Consortium initiative.","volume":"69","author":"Lansky","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"hoi240072r25","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1161\/CIRCULATIONAHA.120.052874","article-title":"Cerebral embolic protection and outcomes of transcatheter aortic valve replacement: results from the Transcatheter Valve Therapy Registry.","volume":"143","author":"Butala","year":"2021","journal-title":"Circulation"},{"issue":"22","key":"hoi240072r26","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1016\/j.jcin.2017.06.037","article-title":"Cerebral embolic protection during transcatheter aortic valve replacement significantly reduces death and stroke compared with unprotected procedures.","volume":"10","author":"Seeger","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"issue":"17","key":"hoi240072r27","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/eurheartj\/ehy847","article-title":"Rate of peri-procedural stroke observed with cerebral embolic protection during transcatheter aortic valve replacement: a patient-level propensity-matched analysis.","volume":"40","author":"Seeger","year":"2019","journal-title":"Eur Heart J"},{"issue":"6","key":"hoi240072r28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.carrev.2019.04.023","article-title":"Clinical outcomes of Sentinel cerebral protection system use during transcatheter aortic valve replacement: a systematic review and meta-analysis.","volume":"21","author":"Ndunda","year":"2020","journal-title":"Cardiovasc Revasc Med"},{"issue":"22","key":"hoi240072r29","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1001\/archinte.167.22.2417","article-title":"Early risk of stroke after transient ischemic attack: a systematic review and meta-analysis.","volume":"167","author":"Wu","year":"2007","journal-title":"Arch Intern Med"},{"issue":"14","key":"hoi240072r30","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1161\/CIR.0000000000000885","article-title":"Considerations for reduction of risk of perioperative stroke in adult patients undergoing cardiac and thoracic aortic operations: a scientific statement from the American Heart Association.","volume":"142","author":"Gaudino","year":"2020","journal-title":"Circulation"},{"issue":"5","key":"hoi240072r31","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jcin.2022.01.007","article-title":"Cerebral embolic protection and stroke-related mortality following transcatheter aortic valve replacement.","volume":"15","author":"Isogai","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"hoi240072r32","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/ccd.29842","article-title":"Use and outcomes of cerebral embolic protection for transcatheter aortic valve replacement: a US nationwide study.","volume":"98","author":"Khan","year":"2021","journal-title":"Catheter Cardiovasc Interv"},{"issue":"17","key":"hoi240072r33","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.4244\/EIJ-D-22-00713","article-title":"Routine cerebral embolic protection in transcatheter aortic valve implantation: rationale and design of the randomised British Heart Foundation PROTECT-TAVI trial.","volume":"18","author":"Kharbanda","year":"2023","journal-title":"EuroIntervention"},{"issue":"7","key":"hoi240072r35","doi-asserted-by":"publisher","first-page":"549","DOI":"10.4244\/EIJ-D-23-00166","article-title":"Cerebral embolic protection during transcatheter heart interventions.","volume":"19","author":"Jimenez Diaz","year":"2023","journal-title":"EuroIntervention"},{"key":"hoi240072r34","unstructured":"Kharbanda? R, Kapadia? S. SENTINEL PROTECTION: a global prospective meta-analysis of the PROTECTED TAVR and BHF PROTECT-TAVI studies. PROSPERO 2022 (CRD42022324160). Updated August 16, 2024. Accessed October 15, 2024. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42022324160"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2825480\/jamacardiology_makkar_2024_oi_240072_1735232932.11633.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T11:02:12Z","timestamp":1736334132000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2825480"}},"subtitle":["A Post Hoc Analysis of the PROTECTED TAVR Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2024.4278","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}